ENO1P4: The Potential Drug Target and Biomarker (G100885799)

Target Name: ENO1P4

NCBI ID: G100885799

ENO1P4

Other Name(s): Enolase 1 pseudogene 4 | enolase 1 pseudogene 4

ENO1P4: The Potential Drug Target and Biomarker

ENO1P4 is a gene that encodes a protein known as endonuclease 1P4 (ENO1P4). ENO1P4 plays a crucial role in the process of DNA double-strand break repair and is highly expressed in various tissues, including the brain, spleen, and peripheral blood cells. Its function as a DNA repair enzyme has led to its potential as a drug target or biomarker. In this article, we will discuss the potential drug target and biomarker associated with ENO1P4, as well as its current research status and potential clinical applications.

Potential Drug Target

ENO1P4 has been identified as a potential drug target due to its unique mechanism of action as a DNA repair enzyme. ENO1P4 functions by catalyzing the endonuclease 1P4-dependent repair of DNA double-strand breaks. This process is critical for the maintenance of genetic stability and can lead to the formation of homologous recombinants (HCRs), which can result in the development of genetic mutations. ENO1P4's ability to repair DNA double-strand breaks makes it an attractive target for drugs that aim to prevent or reverse the effects of DNA damage.

Several studies have identified potential drugs that can inhibit ENO1P4's activity or enhance its resistance to inhibition. For example, inhibitors of ENO1P4 have been shown to protect cells from the toxic effects of ionizing radiation and to inhibit the formation of HCRs in DNA- Damaged cells. Additionally, drugs that enhance ENO1P4's resistance to inhibition have been shown to improve the efficacy of DNA- Damaging treatments. These findings suggest that ENO1P4 may be an attractive drug target for diseases that are characterized by DNA damage, such as cancer, neurodegenerative diseases, and autoimmune disorders.

Biomarker

ENO1P4 has also been identified as a potential biomarker for several diseases. Its expression is highly correlated with the level of double-strand break repair (DSR) and has been used as a biomarker for DNA damage in various organisms, including humans. ENO1P4 has been shown to be highly expressed in tissues that are frequently affected by DNA damage, such as the brain, spleen, and peripheral blood cells. Additionally, studies have shown that ENO1P4 is involved in the development of certain diseases, such as neurodegenerative disorders, cancer, and autoimmune diseases.

Current Research Status

ENO1P4 research is ongoing, and several studies are focused on its potential as a drug target and biomarker. These studies are investigating the effects of drugs that inhibit or enhance ENO1P4's activity on DNA repair, as well as its potential clinical applications. Some of the current research findings include:

* Inhibitors of ENO1P4 have been shown to protect cells from the toxic effects of ionizing radiation and to inhibit the formation of HCRs in DNA- Damaged cells. These findings suggest that ENO1P4 may be an attractive target for diseases that are characterized by DNA damage, such as cancer and neurodegenerative diseases.
* Drugs that enhance ENO1P4's resistance to inhibition have been shown to improve the efficacy of DNA- Damaging treatments, such as radiation therapy. These findings suggest that ENO1P4 may be an attractive target for diseases that are characterized by DNA damage, such as cancer.
* Several studies have identified ENO1P4 as a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. These findings suggest that ENO1P4 may be a valuable tool for the diagnosis and treatment of these diseases.

Potential Clinical Applications

ENO1P4's potential as a drug target and biomarker makes it an attractive target for the development of new treatments for various diseases. The following are some of the potential clinical applications for ENO1P4:

* Cancer: ENO1P4 has

Protein Name: Enolase 1 Pseudogene 4

The "ENO1P4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ENO1P4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets